



WORLD ECONOMIC FORUM



Technology
Pioneer
2007

**FOR IMMEDIATE RELEASE
NEWS RELEASE**

TSX Venture: **AMF**

**AMORFIX ANNOUNCES MICHAEL SONNENREICH AS A NEW DIRECTOR
AND
ESTABLISHMENT OF A SCIENTIFIC ADVISORY BOARD WITH THE
APPOINTMENT OF DR. DON CLEVELAND**

Amorfix also announces Stock Option Awards for 2006-2007

TORONTO, ON, January 10, 2007 – Amorfix Life Sciences Inc. is pleased to announce the appointment of Mr. Michael Sonnenreich to the Company's Board of Directors. "We sincerely welcome Michael, a seasoned industry leader, to our Board," said Graham Strachan, Chair of the Board of Amorfix. "His substantial experience and networks in the global pharmaceutical industry will be an asset as Amorfix continues to pursue its strategic objective of becoming a world leader in the prevention, diagnosis and treatment of brain-wasting diseases."

Mr. Sonnenreich is a graduate of Harvard University Law School, the University of Wisconsin and the University of Madrid. He is the Chairman and CEO of Kikaku America International and President and CEO of Glocal Communications Corp. Ltd. of London. He is Vice Chairman of the Board of PharMa International Corporation of Tokyo, a Director of Asset Advisory Services of Zurich, an Advisor of Johns Hopkins University School of Advanced International Studies and an Overseer of Tufts University Medical School.

Mr. Sonnenreich has been a Board member and Trustee of numerous companies and universities including Scientific American Magazine, Penn Dixie Industries, ABD American Capital Market Funds, the Integra Fund, Medical Tribune International, Continental Steel Inc, Clark University, the Maret School and the Washington National Opera (President). He was President of the National Coordinating Council on Drug Education.

Amorfix today also announced the formation of a Scientific Advisory Board (SAB) led by Dr. Neil Cashman, Chief Scientific Officer for Amorfix, who will step down from the Board of Directors to Chair the SAB. Joining Dr. Cashman is an internationally distinguished expert in ALS and motor neuron diseases, Dr. Don Cleveland. "Amorfix is honoured to have Dr. Cleveland join its SAB to assist us with developing a therapy for ALS in partnership with Biogen Idec" said Dr. Cashman.

Dr. Cleveland received his doctorate from Princeton and was a professor at Johns Hopkins University School of Medicine prior to accepting his current position at the Ludwig Institute at University of California, San Diego, where he is currently director of the laboratory of cell biology. He has published

extensively on adult motor neuron diseases, such as Amyotrophic Lateral Sclerosis, or ALS, the hallmark of which is the selective death of motor neurons.

Dr. Cleveland has received numerous awards including election to the prestigious National Academy of Sciences of the United States, the Sheila Essey Prize from the American Academy of Neurology and the ALS Association, and a NIH MERIT Award from National Institute of General Medicine. He is the only individual to receive two Jacob Javits Neuroscience Investigator MERIT awards from the National Institute of Neurologic Diseases and Stroke. He is an Editor of the Journal of Cell Biology.

Amorfix also reported today that it issued 1,299,500 stock options to directors, employees and consultants with a term of five years, an exercise price of \$1.43 and various vesting schedules. Stock options in the amount of 235,000 were awarded to directors for services performed in 2006 and in the amount of 250,000 stock options for director services for 2007. In addition, senior officers were awarded 369,000 stock options as long term incentive compensation and 204,000 stock options in lieu of cash performance bonuses. Mr. Sonnenreich was also awarded 75,000 stock options as a new director with a term of five years and an exercise price of \$1.40. The option grants are subject to acceptance for filing by the TSX Venture exchange.

About Amorfix

Amorfix is an emerging company focused on the diagnosis and treatment of brain-wasting diseases, where aggregated misfolded proteins (AMPs) are prevalent. Brain AMPs include infectious prions, which cause Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (mad cow disease), scrapie in sheep and the human form, variant Creutzfeldt-Jakob Disease (vCJD). A hallmark of Alzheimer's disease, Amyotrophic Lateral Sclerosis and Parkinson's disease is the accumulation of AMPs in neurons. Amorfix has developed a test procedure to diagnose AMP diseases using a routine blood sample and a novel therapeutic approach for treatment. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, visit the website at www.amorfix.com or contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-482-3812
george.adams@amorfix.com

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-482-3814
james.parsons@amorfix.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.